Transforming Second Line Immunotherapy For
Transforming Second Line Immunotherapy For Information Guide
Introduction on Transforming Second Line Immunotherapy For
Tune into Better Edge as we sit down with Emma Barber, MD, director of Robotic Surgery in the Division of Gynecologic Oncology ... Ghassan K. Abou-Alfa, MD; Mark H. O'Hara, MD; Mark W. Karwal, MD; and A. Ruth He, MD, PhD, highlight the accelerated ... Benjamin Besse, MD, PhD, Institut Gustave Roussy, Paris, France, provides an overview of the status of Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, shares the results from the primary analysis of the Phase ... Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the Phase II KEYNOTE-224 trial ... Jeremy Abramson, MD, Massachusetts General Hospital, Boston, MA, presents results from the Phase III
Do-Youn Oh, MD, PhD, Seoul National University College of Medicine, Seoul, South Korea, discusses Benjamin P. Levy, MD, discusses patient and tumor responses to chemotherapy-based options and Julien Edeline, MD, PhD, Centre Eugene Marquis, Rennes, France, discusses real-world data from the CHIEF cohort, which ... Presented by Justin T. Moyers, MD Phase I & Experimental Therapeutics Program The Angeles Clinic and Research Institute In ... Roy Herbst, MD, PhD; Fred Hirsch, MD, PhD; Suresh Ramalingam, MD; Naiyer Rizvi, MD; and Everett Vokes, MD, discuss the ... Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses the results of the ...
Important Facts
Latest News
Expert Insights
Data is compiled from public records and verified media reports.
Last Updated: May 24, 2026
Final Thoughts
Disclaimer: Disclaimer: Details estimates are based on publicly available data, media reports, and financial analysis. Actual numbers may vary.
